HP
OMED

Harbourvest Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Harbourvest Partners’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,901,106
Closed -$1.42M – 44
2018
Q4 		$1.42M Buy
+1,901,106
New +$2.86M 0.67% 16

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbourvest Partners's OMED Position: Q1 2019 in Review

Harbourvest Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2019, closing a stake of 1,901,106 shares — an estimated $1.42M sold.

Harbourvest Partners first reported a position in OMED in Q4 2018 and held it in 1 quarter. The position peaked at $1.42M in Q4 2018. 41 funds tracked by Wall St. Rank hold OMED as of Q1 2019.

  • Harbourvest Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Harbourvest Partners sold 1,901,106 OncoMed Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.42M.
  • Harbourvest Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Harbourvest Partners's OncoMed Pharmaceuticals, Inc. position peaked at $1.42M in Q4 2018.
  • 41 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2019.

Based on Harbourvest Partners's 13F filing for Q1 2019, filed 13 May 2019.